Leading the development of biosensors with the goal of transforming personal and societal health and wellness by making our body’s chemistry easily accessible
I am pleased to announce that Profusa, Inc. has completed its business combination with NorthView Acquisition Corp. (NVAC), following approval by NVAC’s shareholders. Profusa, Inc. will begin trading on Nasdaq under the ticker “PFSA” on July 14, 2025.
🔗bit.ly/3TAJ2tm
Could carriers of infectious disease be identified before fever or cough symptoms start? Our CEO @BenHwangCA discusses the role our biosensor technology could play via @MDDIonlinebit.ly/39j9e1X
What if we could prevent the spread of #infectiousdiseases by predicting the symptoms before they start? Discover how our biosensor is exploring this notion via @mashablebit.ly/2W2MH6P
A recent study featuring our technology aims to help predict and combat the spread of infectious disease. Our CEO @BenHwangCA’s shares his perspective on the research.
linkedin.com/pulse/profusa-f…
Data presented at #LINC2020 suggest our technology may improve clinical management for patients with #CLI. Find out more about the research: prn.to/2vzjd5a
We’re proud to receive the EU CE Mark for the Wireless Lumee Oxygen Platform – an important step toward expansion in application and geography. prn.to/3aRci7F
What makes Profusa’s biosensors unique? Our CEO @BenHwangCA takes on the #wearables revolution and creating biosensors that work with, not against, the body via @MDDIonlinebit.ly/2YYEcc2
Attending #BIOMEDevice? Today our CEO @BenHwangCA will discuss the role of smart sensors and how it is poised to advance #IoT applications, in-home monitoring and smart drug technologies bit.ly/2XSXrTR